Papillary Thyroid Microcarcinoma Clinical Trial
Official title:
Proper Extent of Surgery for Papillary Microcarcinoma
Although the vast majority of patients with Papillary Thyroid Microcarcinoma (PTMC) have
excellent long-term outcomes, some patients experience tumor recurrence, either locally or,
less frequently, as distant metastases, with some patients dying due to this disease. The
natural course of PTMC has not always been universally accepted, thus creating controversy
concerning the diagnosis and treatment of PTMC. Further, it is not yet possible to
confidently identify PTMCs that would take aggressive courses if left untreated. Treatment
recommendations range from observation alone to vigorous intervention featuring total
thyroidectomy, prophylactic cervical lymph node dissection, and adjuvant RI ablation.
Therefore, no consensus has yet been reached on the biological aggressiveness of PTMC or on
which therapy is the most appropriate. Moreover, the impact of several clinicopathologic
risk factors, including tumor size, is unclear, although patients with tumors ≤ 0.5cm in
diameter may have a better prognosis than patients with tumors 0.5-1 cm in size.
Most studies evaluating the proper extent of surgery for PTMC have been retrospective in
design. A prospective, long-term, randomized study in a large number of patients, however,
may not be feasible owing to the need for an extensive follow-up duration, the costs
associated with such a study, and, particularly, its ethical constraints. Consequently, it
is not currently possible to determine the prognosis of patients with PTMC or the proper
therapeutic approach in these patients. The investigators therefore compared long-term
outcomes after total thyroidectomy (TT: total or near-total thyroidectomy) or less than
total thyroidectomy (LT: lobectomy or subtotal thyroidectomy) in a large cohort of patients
with PTMC, using propensity-score matching to adjust for the uncontrolled assignment of
surgical extent in these patients. In addition, the investigators evaluated whether tumor
size, ≤ 0.5 cm or > 0.5 cm, had a significant impact in determining the extent of surgery in
patients with PTMC.
Study population From March 1986 to December 2006, a total of 5042 patients with PTC (of all
tumor sizes) underwent initial surgical therapy at our institution. Of these, 2441 patients
(48.4%) had PTMCs ≤ 1 cm in diameter, with 1270 undergoing TT and 1171 undergoing LT.
Complete follow-up data for major clinical events were available for 2014 patients (82.5%),
including 1015 (79.9%) of the TT group and 999 (85.3%) of the LT group (p=0.083). Patients
were followed-up for a median 11.8 years (range, 5 to 26 years). All histopathologic
diagnoses were reviewed and verified by endocrine pathologists using WHO criteria. The study
protocol was approved by our Institutional Review Board. Details of patients' presentations,
surgical and pathologic findings, and adjunctive treatments were obtained from the Yonsei
University Thyroid Cancer Database.
Management strategy In patients diagnosed with PTMC after a complete radiologic and
histologic examination, the extent of thyroidectomy and radioactive iodine (RI) therapy were
based on prognostic factors. However, the protocol of our institution as to how PTMC should
be appropriately managed has been changed according to update of clinical reports and
validated treatment guidelines. Therefore, the lack of a standardized approach during the
study period allowed us to assess the impact of various therapeutic modalities, especially
extent of thyroidectomy, in patients with PTMC.
;
Observational Model: Cohort, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04623801 -
Laser Ablation of Papillary Thyroid Microcarcinoma
|
Phase 2 | |
Recruiting |
NCT06333587 -
Minimally Invasive Treatments of the Thyroid
|
||
Suspended |
NCT03327636 -
A Trial Comparing USG-HIFU vs AS in Management of Low-risk PTMC
|
N/A | |
Recruiting |
NCT05189821 -
RFA Treatment for Papillary Thyroid Microcarcinoma
|
||
Active, not recruiting |
NCT02938702 -
Active Surveillance on Papillary Thyroid Microcarcinoma
|
||
Completed |
NCT01384669 -
Genetic Expression Alteration Affect on Lateral Neck Node Metastasis of Thyroid Papillary Microcarcinoma : Microarray Analysis
|
||
Recruiting |
NCT02609685 -
Active Surveillance of Papillary Thyroid Microcarcinoma
|
N/A | |
Active, not recruiting |
NCT04129411 -
Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation
|
N/A | |
Recruiting |
NCT03808779 -
A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma.
|
N/A | |
Not yet recruiting |
NCT04376203 -
Microbiome and Papillary Thyroid Microcarcinoma
|
||
Recruiting |
NCT03432299 -
Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma
|
N/A |